research Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
In this study, combining deferasirox with sorafenib significantly reduced liver fibrosis and preneoplastic lesions in rats while also lessening adverse effects compared to sorafenib alone.